The
Intellectual Property Owners Association (IPO) will offer a one-hour webinar
entitled "Myriad: Implications of
the U.S. Supreme Court Opinion" on June 18, 2013 beginning at 2:00
pm (ET).  A panel consisting of Gregory Castanias of Jones Day (who argued
for Myriad at the Federal Circuit and before the U.S. Supreme Court); Patent Docs author Dr. Kevin Noonan of
McDonnell Boehnen Hulbert & Berghoff; and Paul Golian, Assistant General
Counsel at Bristol-Myers Squibb Company will consider such questions as:

•
How many and which existing gene patents will be challenged in post-grant
proceedings at the USPTO?
•
Will holders of gene patents seek reissue?
•
What does the decision mean for protein therapeutics, and other products that
are arguably "found in nature"?
•
Are claims to isolated polypeptide sequences covering human proteins that are
in therapeutic use no longer valid?
•
Where do comparative diagnostic claims stand after both Myriad and Prometheus?

The
registration fee for the webinar is $120 (government and academic rates are
available upon request).  Those
interested in registering for the webinar can do so here.